AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Follow-Up Questions
Who is the CEO of AstraZeneca PLC?
Mr. Pascal Soriot is the Chief Executive Officer of AstraZeneca PLC, joining the firm since 2012.
What is the price performance of AZN stock?
The current price of AZN is $82.31, it has increased 0.34% in the last trading day.
What are the primary business themes or industries for AstraZeneca PLC?
AstraZeneca PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is AstraZeneca PLC market cap?
AstraZeneca PLC's current market cap is $255.2B
Is AstraZeneca PLC a buy, sell, or hold?
According to wall street analysts, 26 analysts have made analyst ratings for AstraZeneca PLC, including 10 strong buy, 19 buy, 5 hold, 0 sell, and 10 strong sell
